Reply to activity and safety of dose-adjusted infusional cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy with rituximab in very elderly patients with poor-prognostic untreated diffuse large B-cell non-Hodgkin lymphoma.

摘要

We would like to thank Fabbri et al for their interest in our article and the provision of very compelling comments. Fabbri et al draw attention to an important topic in geriatric oncology: the use of comprehensive geriatric assessment (CGA) for older patients with cancer. They conclude that a broader application of CGA, which was not used in our study for patient selection, could lead to a better selection of patients and, consequently, studies with more comparable results.Although several low-dose chemotherapy regimens for elderly patients have been proposed, the regimen of rit-uximab plus full doses of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is recognized as the gold standard treatment for elderly patients with diffuse large B-cell non-Hodgkin lymphomas (DLBCL).